Literature DB >> 31605817

A de novo frameshift FGFR1 mutation extending the protein in an individual with multiple epiphyseal dysplasia and hypogonadotropic hypogonadism without anosmia.

Marjolaine Champagne1, Patricia Olivier2, Peter Glavas3, Marie-Andrée Cantin3, Frank Rauch4, Nathalie Alos2, Philippe M Campeau5.   

Abstract

Multiple epiphyseal dysplasia (MED) is a genetically and clinically heterogeneous disease with both dominant and recessive inheritance. Eight different genes are known to cause the disease but in 15% of cases of MED, no mutation is found. Fibroblast growth factor receptor 1 (FGFR1) is a crucial regulator of bone formation and when mutated, can cause diseases with skeletal manifestations; nevertheless, MED has not been described in individuals with FGFR1 mutations. In this report, we describe a proband with MED and congenital normosmic hypogonadotropic hypogonadism (HH). DNA analysis showed a de novo frameshift variant in FGFR1 likely explaining the HH (p.Arg852Thrfs*165). No other mutation was found after a large gene sequencing panel, exome sequencing and an array CGH, except for a variant of unknown significance in FBN1 (rs755375255), but there were no features of a disease associated with FBN1 mutations and this variant is found a few times in population databases. We thus discuss the possibility that MED might be a new skeletal feature associated with FGFR1 mutations.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  FGFR1; Fibroblast growth factor receptor 1; Hypogonadotropic hypogonadism; MED; Multiple epiphyseal dysplasia

Year:  2019        PMID: 31605817     DOI: 10.1016/j.ejmg.2019.103784

Source DB:  PubMed          Journal:  Eur J Med Genet        ISSN: 1769-7212            Impact factor:   2.708


  1 in total

1.  Abnormal eruption of teeth in relation to FGFR1 heterozygote mutation: a rare case of osteoglophonic dysplasia with 4-year follow-up.

Authors:  Yuchun Zou; Hanyu Lin; Weijia Chen; Lin Chang; Senxin Cai; You-Guang Lu; Linyu Xu
Journal:  BMC Oral Health       Date:  2022-02-11       Impact factor: 2.757

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.